

Curriculum Vitae

**Hendrik Henri Versteeg, PhD.
Professor of Internal Medicine
Leiden University Medical Center**

Date December 1, 2016



1 Personal information

Titles, first names, surname, Birth Date Nationality	Prof. dr. Hendrik Henri Versteeg December 22, 1974 Dutch
Professional Address	Leiden University Medical Center, Room C7-14 Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Professional Phone Number Email	0031-71-5263872 h.h.versteeg@lumc.nl
Home Address	Vlindersingel 133, 3544 VC, Utrecht, The Netherlands
Private Phone Number Email	0031-6-13198715 henkv873@gmail.com
Preferred contact address:	Leiden University Medical Center, Room C7-14 Albinusdreef 2, 2333 ZA, Leiden, The Netherlands 0031-71-5263872 h.h.versteeg@lumc.nl
Web sites:	http://www.eindhovenlaboratory.com/henri-versteeg-phd/ https://www.researchgate.net/profile/Henri_Versteeg http://f1000.com/prime/thefaculty/member/5637971022452463 https://www.linkedin.com/pub/henri-versteeg/24/619/a74

2 Education and Training

Education

May 13, 2003: PhD. Name institution: University of Amsterdam, Faculty of Medicine. Specialty: Internal Medicine. Title thesis: FVIIa-induced signal transduction; potential explanations for TF-

Curriculum Vitae Henri Versteeg

Sept 28, 1998: associated events. Thesis supervisors: Prof S.J. van Deventer, Prof D.J. Richel, dr M.P. Peppelenbosch
MSc in Biology. Name institution: Utrecht University, Faculty of Biology. Specialty: Cell biology. Title thesis: Cyclooxygenase-dependent signaling: molecular events and consequences. Thesis supervisors: Prof A.J. Verkleij, dr P.M.P. van Bergen en Henegouwen.

Post Graduate Education and Training

Training positions

Mar 2007-Mar 2009: Senior postdoctoral fellow. Dept of Thrombosis and Hemostasis, Leiden University Medical Center, The Netherlands. Mentor: Prof P.H. Reitsma
May 2004-Feb 2007: Postdoctoral fellow, Dept of Immunology, The Scripps Research Institute, La Jolla, CA, USA. Mentor: Prof W. Ruf
Jan 2003-Apr 2004: Postdoctoral fellow, Dept of Medical Oncology, Academic Medical Center Amsterdam, The Netherlands. Mentor: Prof D.J. Richel

Educational qualifications

May 2016: University Teaching Qualification (BKO)
June 2014: Effective Leadership. Institution: LUMC/Bureau Engelsman
Sep 2008: Experimental animal course (Article 9). Institution: LUMC
Nov 1999: Radioisotope course level 5B. Institution: AMC

3 Employment History

Academic Appointments

Apr 2015-present: Professor, Dept of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, The Netherlands
Jun 2012-Mar 2015: Associate professor, Dept of Thrombosis and Hemostasis, Leiden University Medical Center, The Netherlands
Apr 2009-May 2012: Assistant professor, Dept of Clinical Oncology, Leiden University Medical Center, The Netherlands

Editorial Duties

2017: Editorial Board, Carcinogenesis (Oxford University Press)
2016: Editor-in-Chief, Thrombosis Research (Elsevier)

2015: Editorial board, Thrombosis Research (Elsevier)

Professional Society Memberships

2013: Member of the ISTH subcommittee on Malignancy and Thrombosis.

2011: Member of the American Society of Hematology (ASH).

2011: Member of the International Society on Thrombosis and Haemostasis (ISTH).

2009: Associate member Faculty of 1000 (F1000), a post-publication peer review organization.

2000: Member of the Dutch Society on Thrombosis and Haemostasis.

Honours and Awards

2012: Marie Parijs award (€2,500) for best translational research at the Leiden University Medical Center.

2006: New Investigator Award (\$1,000), awarded at the 7th annual conference on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) in Denver, CO, USA

2003: The Novo Nordisk Haemostasis Award 2003 (€15,000), on research describing the role of the signal transducers Jak2 and STAT5 in FVIIa:TF-associated (patho)physiology.

4 Administrative Activities and Responsibilities

Institutional Activities and Responsibilities

Institutional activities

2016-present: Member of the science committee (wetenschapscommissie) of the Department of Internal Medicine

2015-present: Member of the management team of the Department of Internal Medicine

2015-present: Scientific chair of the Thrombosis and Hemostasis Division

2015: Member of the Experimental Animal Welfare committee (Instantie voor Dierenwelzijn)

2013: Feasibility studies on relocation of the Eindhoven Laboratory for Experimental Vascular Medicine to the D4 tower, and integration with the Laboratory of Endocrinology. Role taken: committee member.

2013: Setting up web sites for the Department of Thrombosis and Hemostasis. Role taken: web site manager

Curriculum Vitae Henri Versteeg

- 2012: Establishment of an inventory list of reagents within the LUMC, to facilitate exchange of reagent between researchers. Role taken: initiator.
- 2012: Internal evaluation of major (inter)national grant applications and rehearse sessions with the applicants, within the LUMC. Role taken: committee member.

Administrative roles

- 2007-2014: Management of the Division of Thrombosis and Hemostasis. Management of a research team on the interplay between blood coagulation and cancer. Tasks include budget control, yearly evaluations.

Ph.D. thesis committees (role: member)

Keren Borensztajn (2009, University of Groningen), Yuana Yuana (2011, University of Leiden), Kun Shi (2015, University of Amsterdam), Dafna Groeneveld (2015, University of Leiden), Wesley Utomo (2015, Erasmus University), Eugenio Zoni (2016, University of Leiden).

Ph.D. thesis committees (role: secretary)

Yihao Li (2016, University of Leiden), Jasmijn Timp (2016, University of Leiden), Madelon Paauwe, 2016).

Local, National and International Activities and Responsibilities

National Activities

- 2017: Member of the NWO-VENI selection committee.
- 2016: Chair of the NWO Rubicon selection committee.
- 2014: Member of the NWO Rubicon selection committee.
- 2012: Participation in De Jonge Akademie on Wheels, organized by “De Jonge Akademie”.
- 2012: Participation in Workshop “Tussen Lab en Leven” organized by the Netherlands Heart Foundation. Participation involved guided tours in the laboratory and public education on cardiovascular diseases.
- 2008: Reviewer for The Netherlands Heart Foundation, The Netherlands Organization for Scientific Research (NWO).
- 2000: Organization of a course on a phospho-specific antibody cell-based ELISA that the writer of this CV has developed.

International Activities

- 2016-2017: International Advisory Board, 26th Congress of the International Society on Thrombosis and Haemostasis in Berlin, Germany.
- 2013-2017: Selection committee member, Pathophysiology Section of the French National Research Agency (ANR).
- 2003-2016: Reviewer for the following journals: Apoptosis, Arteriosclerosis, Thrombosis and Vascular Biology, Biomed Central Cancer, Blood, BBA Molecular Cell Research, Blood Coagulation and Fibrinolysis, Cellular and Molecular Life Science, Cytokine, Expert Opinion on Biological Therapies, Frontiers in Bioscience, Haematologica, Journal of Surgical Research, International Journal of Cancer, Molecular Carcinogenesis, Journal of Thrombosis and Haemostasis, Leukemia, Molecular and Cellular Biology, Thrombosis and Haemostasis, Thrombosis Research.
- 2013: Organization of international conferences; member of the subcommittee on Coagulation and Fibrinolysis for the 24th Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, 2013.
- 2007-2014: Reviewer for the Association for International Cancer Research (AICR), Austrian Science Fund, Cancer Research UK, Diabetes UK, Yorkshire Cancer Research.
-

5 Teaching Activities and Responsibilities

Teaching Activities and Responsibilities

Basic sciences

- 2015-present: Coordinator of the course Physiology Advanced Concepts, 2nd year biomedical master students at the LUMC
- 2007-2015: Frontiers of Science course for 2nd year biomedical master students at LUMC. Role taken: lecturer (3 hrs/course), and mentor (12 hrs/course).
- 2007-2015: Training of a total of 14 master students, 8 PhD students and 1 postdoctoral fellow in laboratory-based research at LUMC. Role taken: supervisor (20 hrs per week).
- 2007-2012: Yearly lectures to PhD students on Thrombosis and Haemostasis during the course “Thrombosis and Haemostasis” organized by The Netherlands Heart Foundation. Role taken: lecturer (1 hr/course)

Clinical sciences:

- 2014-present: Half minor ‘Heart and Blood Vessels’ for 3rd year medical students (as a part of the new curriculum) at LUMC. Role taken: lecturer (2 hrs/course)

- 2012: Application course for Internists, organized by Federation of Dutch Thrombosis services. Role taken: lecturer (2 hrs/course)
- 2009-2013: Pathophysiology course for 2nd year medical students at LUMC. Role taken: mentor (6 hrs per course).
- 2009-2012: Genes and Environment, for 2nd year medical students at LUMC. Role taken: mentor (6 hrs per course).
- 2008-2014: Research competence course 'Vascular Medicine' at LUMC. Role taken: lecturer (3 hrs/course).

Received Teaching Qualification (BKO) in 2016.

6 Research

Main Research Themes

The main interest of the writer of this CV is the involvement of the hemostatic system in non-hemostatic processes such as cancer, metastasis, angiogenesis and inflammation. In addition, focus is put on the role of blood clotting factors in cancer-associated thrombosis. I have elucidated the mechanisms by which blood clotting factors such as the tissue factor (TF)/VIIa complex and the ternary TF/VIIa/Xa complex influence cellular behavior and have successfully attempted to link these phenomena to (patho)physiological processes such as cancer. One aspect of my research includes the regulation of TF function in hemostasis and in intracellular signaling; I have found that distinct forms of TF regulate hemostasis and signaling, and that disulfide isomerisation by the protein PDI switches TF from coagulation to cellular signaling.

Recently, I have shifted my focus towards the relevance of coagulation factors and their receptors PAR1 and PAR2 in cancer progression, generation of cancer stem cells and cancer-associated thrombosis, using orthotopic and genetic *in vivo* models. Furthermore, analysis of coagulation factor and receptor expression in large-scale cancer patient cohorts are conducted. Finally, effort is put into identifying targets within the coagulation cascade that can be targeted in anti-thrombotic and anti-cancer strategies.

Supervision (theses)

- Dec 2019 (expected): Julia Tilburg, MSc. Leiden University Medical Center. Role taken: promotor
- Sept 2018 (expected): Khang Tran, MSc. Academic Medical Center, Amsterdam. Role taken: promotor
- Sept 2018 (expected): Chantal Kroone, MSc. Leiden University Medical Center. Role taken: promotor
- Sept 2017 (expected): Betül Unlü, MSc. Leiden University Medical Center. Role taken: promotor
- Feb 2017 (expected): Christiaan Tieken, MSc. Leiden University Medical Center. Role taken: promotor

Curriculum Vitae Henri Versteeg

- April 2015: Begum Kocaturk, MSc. Leiden University Medical Center.
Role taken: co-promotor
- Oct 2013: Yascha W. van den Berg. Leiden University Medical
Center. Role taken: co-promotor
- Feb 2013: Lisa van den Hengel, PhD. Leiden University Medical
Center. Role taken: co-promotor
- June 2008: Lois W. Brüggemann, PhD. Academic Medical Center.
Role taken: co-promotor

Supervision (postdocs)

- Dec 2013-Nov 2014: Araci da Rocha Rondon
- Oct 2015-March 2016: Eliana Stanganello, PhD
- Nov 2015-current: Jeroen Buijs, PhD
- July 2016-current: Madelon Paauwe

Local, National and International Research Collaborations

National and international activities

- 2014-present: Dr. N Iversen, Oslo University Hospital and University of Oslo,
Norway. (The role of FV in breast cancer).
- 2014-present: Dr U. Ulbricht, Bayer Healthcare Pharmaceuticals, Wuppertal,
Germany. (Generation of isogenic transformed mammary epithelial
cells).
- 2013: Dr E. Rabizadeh, Rabin Medical Center, Petah Tikva, Israel.
(Fibrinogen-like protein 2 in cancer).
- 2013-present: Dr C.C. Kirwan and H. Shaker, Paterson Institute for Cancer
Research, Manchester, UK. (TF and tumor stemness).
- 2013-present: Prof. L. Badimon, Institut Català de Ciències Cardiovasculars,
Barcelona, Spain. (TF-integrin interplay in angiogenesis).
- 2012-present: Dr. R. Merks, Netherlands Institute for Systems Biology,
Amsterdam, The Netherlands (Computer modeling of angiogenic
networks).
- 2012-present: Dr. J.L. Degen, Cincinnati's Children's Hospital Medical Center,
USA. (Role of asTF in tumor biology).
- 2012-present: Dr. R. de Queiroz Monteiro, Federal University of Rio de Janeiro,
Brazil. (TF signaling in cancer stem cells).
- 2012-present: Prof. J. Rak, McGill University Montreal, Canada. (TF expression
in Glioblastoma).
- 2011-present: Dr. J. Roelofs, Academic Medical Center Amsterdam, The
Netherlands, (Development of a large-scale pancreatic cancer
tissue array).
- 2011: Prof. F Tanner, University of Zurich, Switzerland. (The role of TF
disulfide switching in murine models of embryogenesis,
angiogenesis and inflammation).

Curriculum Vitae Henri Versteeg

- 2009-present: Dr P. Kuppen and Dr. G.J. Liefers, Dept. of Surgery at the LUMC, The Netherlands. (The role of coagulation factor expression in breast cancer).
- 2007-present: Dr V.Y. Bogdanov, University of Cincinnati, USA. (asTF in cancer and blood clotting).
- 2007-present: Prof. W. Ruf, The Scripps Research Institute, USA. (The role of full length TF and FVIIa in tumor angiogenesis as well as in TF decryption in thrombosis settings).
- 2007-present: Prof. N. Mackman, University of North Carolina, USA. (The role of coagulation factors and their receptors in vascular remodeling (arteriogenesis) in murine models of ischemia).
- 2007-present: Dr. C.A. Spek, Academic Medical Center Amsterdam, The Netherlands. (The role of the coagulation factor receptor PAR2 in tumor angiogenesis and inflammatory bowel disease using murine models).
- 2007-2009: Dr. M. Hoylaerts and dr. R. Lijnen, University of Leuven, Belgium. (Generation of a TF disulfide switch mouse model).
- 2003: Dr. J. Heyman, Active Motif, Belgium, on the setup of a commercially available cell-based ELISA.
- 1999-2003: Dr. L.C. Petersen and dr. B.B. Sørensen, Novo Nordisk, Denmark. (TF:FVIIa-induced protein synthesis and cell survival in tumor cells).
- 1999-2000: Prof. P.J. Coffey, Utrecht University, The Netherlands. (The set-up of a cell-based ELISA using antibodies directed against phosphorylated signal transduction proteins).

Grant Support

Active funding

- 2016-2018: A two year LUMC bridging fund for ERC reserve list candidates. Total budget: €100,000.
- 2015-2019: A four-year Dutch Cancer Society (KWF) project, entitled “Effects of tumor-expressed coagulation factors on cancer stem cells and breast cancer progression.” Role taken: sole applicant. Total budget: €560,200.
- 2015-2018: A three-year Worldwide Cancer Research (formerly AICR) project, entitled “The role of tumor-expressed clotting factors in breast cancer progression”. Role taken: sole applicant. Total budget: €266,000.
- 2015: De Merel Fund project on thrombosis in colorectal cancer patients. Role taken: main applicant. Other applicant: Dr. S.C. Cannegieter, LUMC. Total budget: €50,000.
- 2014-2018: A four-year collaborative Rembrandt Institute on Cardiovascular Science (RICS) grant for a Ph.D. student, entitled “LIM-domain-only protein FHL-2 modulates Tissue Factor activity, venous thrombosis

Curriculum Vitae Henri Versteeg

and angiogenesis”. Other main applicant: Prof C. de Vries, AMC, Amsterdam. Total budget: €480,000.

2014: A one year grant from LUF/Den Dulk-Moermans fund, entitled “Identification of genes and proteins at the basis of cancer-associated thrombosis. Role taken: sole applicant. Total budget: €15,000.

2009-2014: A five-year VIDI fellowship awarded by the Netherlands Organization for Scientific Research (Nederlandse Wetenschapsorganisatie; NWO) on a grant proposal entitled; “The role of tissue factor isoforms in cancer and tumor angiogenesis.” Role taken: sole applicant. Total budget: €800,000.

Completed funding

2009-2010: A one-year intramural grant for a technician, awarded by the Kassenaar Foundation. Role taken: sole applicant. Total budget: €50,000

2007-2010: A three-year grant for a graduate student awarded by the Leducq Initiative against Thrombosis (LINAT) on a grant proposal entitled: ”The role of TF:fvIIa signaling in angiogenesis and sepsis” Role taken: sole applicant. Total budget: €150,000

2007-2010: A three-year VENI fellowship awarded by the Netherlands Organization for Scientific Research (Nederlandse Wetenschapsorganisatie; NWO) on a grant proposal entitled; “The role of tissue factor signaling in angiogenesis.” Second-best rated proposal out of >100. Role taken: sole applicant. Total budget: €200,000. Peer-reviewed.

2006-2008: A two-year AHA fellowship awarded by the American Heart Association on a grant proposal entitled ”Regulation of TF activity by s-Nitrosylation ” (percentile rank:1.72). Role taken: sole applicant. Total budget: \$90,000. Peer-reviewed.

2005-2006: A Talent stipend, awarded by the Netherlands Organization for Scientific Research (Nederlandse Wetenschapsorganisatie; NWO) on a grant proposal entitled; “The role of tissue factor in breast cancer.” Role taken: sole applicant. Total budget: \$33,160

Patents, Inventions and Copyrights

1. Development of a phospho-specific antibody cell-based ELISA that has been marketed by a number of biotech companies, among which Active Motif.
2. An antibody against TF that inhibits TF signaling but not coagulation (mAb10H10) and efficiently downregulates breast tumor growth in murine models has been patented (Patent application PCT/US2006/043313 entitled “Compositions and methods for controlling Tissue Factor signaling specificity”, filed on November 6, 2006).
3. An antibody against alternatively spliced TF (asTF) that inhibits asTF signaling (RabMab1) and efficiently downregulates breast tumor growth in

murine models has been patented (U.S. Patent Application Serial No.: 13/747,405 Entitled: METHOD INHIBITING CELL PROLIFERATION INDUCED BY ALTERNATIVELY SPLICED TISSUE FACTOR).

7 Major Invited Lectures

- Jun 2016: Lecture at the Nordic Coagulation meeting, Oslo, Norway
- Jun 2016: Lecture at the meeting of the European Hematology Association, Copenhagen, Denmark
- Apr 2016: Plenary lecture at the International Conference on Thrombosis and Haemostasis Issues in Cancer, Bergamo, Italy.
- Sept 2015: Lecture at the ESC Congress, London, United Kingdom
- July 2014: Symposium lecture at the Frontiers in Cardiovascular Biology meeting, organized by the European Society on Cardiology, Barcelona, Spain.
- May 2014: Plenary lecture at the International Conference on Thrombosis and Haemostasis Issues in Cancer, Bergamo, Italy.
- April 2014: State-of-the-Art Lecture at the 1st Etiology of VENous Thrombosis (EVENT) Symposium, Spitsbergen, Norway.
- Feb 2014: State-of-the-Art Lecture at the 58th meeting of the German Society of Thrombosis and Hemostasis (GTH), Vienna, Austria
- Sept 2013: Seminar at the Eurothrombosis meeting, organized by the European Society on Cardiology, Uppsala, Sweden
- July 2013: Lecture at the 59th ISTH Scientific and Standardization Committee meeting, organized by the International Society on Thrombosis and Haemostasis in Amsterdam, The Netherlands.
- July 2013: State-of-the-Art lecture at the 24th Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, The Netherlands.
- Sept 2012: Plenary lecture at the 4th symposium on Oncobiology, Federal University of Rio de Janeiro.
- Sept 2012: Lecture at the meeting of the British Atherosclerosis Society, Cambridge, UK.
- June 2012: Hematology-in-Focus lecture at the 17th meeting of the European Hematology Association in Amsterdam, The Netherlands.
- April 2012: Plenary lecture at the International Conference on Thrombosis and Haemostasis Issues in Cancer, Bergamo, Italy.
- Nov 2011: Seminar at IQ products, Groningen, The Netherlands.
- July 2011: Symposium lecture at the 23rd meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.
- Oct 2010: Lecture at the Leiden University Medical Center Internal Medicine Day

Curriculum Vitae Henri Versteeg

- Feb 2010: Lecture at the joint meeting of the German Society of Thrombosis and Hemostasis (GTH) and the Dutch Society for Thrombosis and Hemostasis (NVTH) in Nürnberg, Germany.
- Feb 2010: Educational lecture at the meeting of the German Society of Thrombosis and Hemostasis (GTH)/Dutch Society for Thrombosis and Hemostasis (NVTH) in Nürnberg, Germany.
- Sept 2008: Seminar at CIMA (Center for Applied Medical Research), Pamplona, Spain.
- July 2003: Lecture at the 19th meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Birmingham, UK.
- Nov 2000: Presentation at the millennium meeting of the German Signal Transduction Society
-

8 List of Publications

Citation report (Web of Science)

H-index:	30
Number of publications:	82
Sum of the times cited:	3287
Average citations per item:	31.4
Number of first authorships:	25
Number of last authorships:	27

Journal articles

1. Rodger M, Versteeg HH. Striking the right balance. **Thromb Res.** 2016;147:126
2. Versteeg HH, Rodger M. World Thrombosis Day. **Thromb Res.** 2016;146:105.
3. Rodger M, Versteeg HH. We're number 3. **Thromb Res.** 2016;145:129
4. Shaker H, Harrison H, Clarke R, Landberg G, Bundred NJ, Versteeg HH, Kirwan CC. Tissue Factor promotes breast cancer stem cell activity in vitro. **Oncotarget.** Accepted.
5. Rodger M, Versteeg HH. An inflammatory fascination for thrombosis. **Thromb Res.** 2016;144:224-5.
6. Rodger M, Versteeg H. Tribute to Editor in Chief Per Morten Sandset. **Thromb Res.** 2016;143:149.
7. Versteeg HH, Rodger M. Science as a money-spinner? **Thromb Res.** 2016;142:57.
8. Rodger M, Versteeg HH. Changing the guard. **Thromb Res.** 2016;141:196-7.
9. Tieken C, Versteeg HH. Anticoagulants versus cancer. **Thromb Res.** 2016;140:Suppl 1:S148-53.
10. Unruh D, Ünlü B, Lewis CS, Qi X, Chu Z, Sturm R, Keil R, Ahmad SA, Sovershaev T, Adam M, Van Dreden P, Woodhams BJ, Ramchandani D, Weber GF, Rak JW, Wolberg AS, Mackman N, Versteeg HH, Bogdanov VY. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. **Oncotarget.** 2016;doi: 10.18632/oncotarget.7955.
11. Tieken C, Verboom MC, Ruf W, Gelderblom H, Bovée JV, Reitsma PH, Cleton-Jansen AM, Versteeg HH. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. **Thromb Haemost.** 2016;115:1025-33.

Curriculum Vitae Henri Versteeg

12. Versteeg HH. Tissue factor: old and new links with cancer biology. **Semin Thromb Hemost.** 2015;41:747-55.
13. Bogdanov VY, Versteeg HH. Soluble Tissue Factor” in the 21st century: definitions, biochemistry, and pathophysiological role in thrombus formation. **Semin Thromb Hemost.** 2015;41:700-7.
14. Kocatürk B, Versteeg HH. Orthotopic Injection of Breast Cancer Cells into the Mammary Fat Pad of Mice to Study Tumor Growth. **J Vis Exp.** 2015;doi: 10.3791/51967
15. Kooiman J, den Exter PL, Kilicsoy I, Cannegieter SC, Eikenboom J, Huisman MV, Klok, FA, Versteeg HH. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. **J Thromb Haemost.** 2015;13:1683-93.
16. Ünlü B, Versteeg HH. Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? **Thromb Res.** 2014;133, Suppl 2 ():S76-84.
17. Bijkerk R, van Solingen C, de Boer HC, van der Pol P, Khairoun M, de Bruin RG, van Oeveren-Rietdijk AM, Lievers E, Schlagwein N, van Gijlswijk DJ, Roeten MK, de Vries AA, Rodijk M, Pike-Overzet K, van den Berg YW, Versteeg HH, Reinders ME, Staal FJ, van Kooten C, Rabelink TJ, van Zonneveld AJ. MicroRNA-126 in hematopoietic stem cells protects against renal ischemia reperfusion injury by promoting vascular integrity. **J Am Soc Nephrol.** 2014;25:1710-22.
18. Versteeg HH, Ruf W New helpers in TF-dependent migration. **J Thromb Haemost.** 2013;11:1877-9.
19. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. **Blood.** 2013;122:1712-23.
20. Kocatürk B, Versteeg HH. Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill. **J Thromb Haemost.** 2013;11 Suppl 1:285-93.
21. Kocatürk B, Van den Berg YW, Tieken C, Mieog JS, de Kruijf EM, Engels CC, van der Ent MA, Kuppen PJ, Van de Velde CJ, Ruf W, Reitsma PH, Osanto S, Liefers GJ, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor promotes breast cancer growth in a $\beta 1$ integrin-dependent manner. **Proc Natl Acad Sci U S A.** 2013;110:11517-22.
22. Unruh D, Turner K, Srinivasan R, Kocatürk B, Qi X, Chu Z, Aronow BJ, Plas DR, Gallo CA, Kalthoff H, Kirchofer D, Ruf W, Ahmad SA, Lucas FV, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. **Int J Cancer.** 134 (2014):9-20.
23. van den Hengel LG, Hellingman AA, Nossent AY, van Oeveren-Rietdijk AM, de Vries MR, Spek CA, van Zonneveld AJ, Reitsma PH, Hamming JF, de Boer HC, Quax PH, Versteeg HH. Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model. **PLoS One.** 2013;8:e61923.
24. Safdar H, Cheung KL, Salvatori D, Versteeg HH, Laghmani el H, Wagenaar GT, Reitsma PH, van Vlijmen BJ. Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production. **Blood.** 2013;121:4413-6.
25. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. **Physiol Rev.** 2013;93:327-58.
26. van den Hengel LG, van Steijn-van Tol AQ, Bertina RM, Versteeg HH, Osanto S. Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients. **Thromb Res.** 2013;131:187-9.

27. van den Hengel LG, Osanto S, Reitsma PH, Versteeg HH. Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide. **Haematologica**. 2013;98:153-8.
28. Kocatürk B, Versteeg, HH. Tissue Factor isoforms in cancer and coagulation; may the best isoform win. **Thromb Res**. 2012;129:Supplement 1:S46-49
29. Godby RC, Van Den Berg YW, Srinivasan R, Sturm R, Hui DY, Konieczny SF, Aronow BJ, Ozhegov E, Ruf W, Bogdanov VY, Versteeg HH. Non-Proteolytic Properties of Murine Alternatively Spliced Tissue Factor: Implications for Integrin-Mediated Signaling in Murine Models. **Mol Med**. 2012;18:771-9.
30. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. **Arterioscler Thromb Vasc Biol**. 2012;32:563-8.
31. Van den Hengel LG, van den Berg YW, Reitsma PH, Bos MH, Versteeg HH. Evolutionary Conservation of the Tissue Factor Disulfide Bonds and Identification of a Possible Oxidoreductase Binding Motif. **J Thromb Haemost**. 2012;10:161-2.
32. Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. **Blood**. 2012;119:924-32.
33. Van den Hengel LG, Kocatürk B, Reitsma PH, Ruf W, Versteeg HH. Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor. **Blood**. 2011;118:3446-3448.
34. Srinivasan R, Ozhegov E, van den Berg YW, Aronow BJ, Franco RS, Palascak MB, Fallon JT, Ruf W, Versteeg HH, Bogdanov VY. Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling. **J Thromb Haemost**. 2011;9:2087-2096.
35. Versteeg, H.H., Ruf, W. Thiol pathways in the regulation of tissue factor prothrombotic activity. **Curr Opin Hematol**. 2011;18:343-348.
36. Queiroz KC, Van 't Veer C, Van Den Berg Y, Duitman J, Versteeg HH, Aberson HL, Groot AP, Verstege MI, Roelofs JJ, Te Velde AA, Spek CA. Tissue factor-dependent chemokine production aggravates experimental colitis. **Mol Med**. 17 (2011): 1119-1126.
37. Van den Hengel LG, Versteeg HH. Tissue Factor signaling: a multi-faceted function in biological processes. **Front Biosci (Schol Ed)**. 2011;3:1500-10.
38. Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. **Blood**. 2010;116:6106-6113.
39. Van den Berg YW, Versteeg HH. Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes? *Hamostaseologie*. 2010;30:144-149.
40. Ruf W, Versteeg HH. Tissue factor mutated at the allosteric Cys186-Cys209 disulfide bond is severely impaired in decrypted procoagulant activity. **Blood**. 2010;116: 500-501.
41. Van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. **Proc Natl Acad Sci U S A**. 2009;106:19497-19502.
42. Niers TM, Brüggemann LW, Van Sluis GL, Liu RD, Versteeg HH, Büller HR, Van Noorden CJ, Reitsma PH, Spek CA, Richel DJ. Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. **J Thromb Haemost**. 2009;7:1595-1597.
43. Diks SH, Sartori da Silva MA, Hillebrands JL, Bink RJ, Versteeg HH, van Rooijen C, Brouwers A, Chitnis AB, Peppelenbosch MP, Zivkovic, D. d-Asb11 is an essential mediator of canonical Delta-Notch signalling. **Nat Cell Biol**. 2008;10:1190-1198.
44. Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the

Curriculum Vitae Henri Versteeg

- development of mammary adenocarcinoma in polyoma middle T mice. **Cancer Res.** 2008;68:7219-7227
45. Versteeg HH, Borensztajn KS, Kerver ME, Reitsma PH, Spek CA, Peppelenbosch MP, TF:VIIa-specific activation of CREB upregulates proapoptotic proteins via PAR2. **J Thromb Haemost.** 2008;6:1550-1557.
 46. Brüggemann LW, Versteeg HH, Reitsma PH, Spek CA. High factor VIIa levels do not promote tumor metastasis. **Thromb Haemost.** 2008;99:787-788.
 47. Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. **J Cell Mol Med.** 2008;12:2622-2627.
 48. Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, Buckle T, Van Noorden CJ, van Tellingen O. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. **Biotechniques** 2007;43 Suppl 1: 7-13.
 49. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. **Blood.** 2008;111: 190-199.
 50. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein disulfide isomerase independent of oxido-reductase activity. **J Biol Chem.** 2007;282: 25416-25424.
 51. Borensztajn KS, Bijlsma MF, Groot AP, Brüggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP, Spek CA. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. **Exp Cell Res.** 2007;313:2622-2633.
 52. Versteeg HH, Ahamed J, Kerver ME, Chen VM, Mueller BM, Hogg PJ, Ruf, W. Disulfide isomerization switches Tissue Factor from coagulation to cell signaling. **Proc. Natl. Acad. Sci. USA.** 2006;103:13932-13937.
 53. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of Tissue Factor by an allosteric disulfide bond. **Biochemistry** 2006;45: 12020-12028.
 54. Versteeg HH, Ruf W. Emerging insights in Tissue Factor signal transduction. **Semin. Thromb. Hemost.** 2006;32:24-32
 55. Martins-Cavagis, A.D., Ferreira, C.V., Versteeg, H.H., Assis, C.F., Bos, C.L., Bleuming, S.A., Diks, S.H., Aoyama, H., Peppelenbosch, M.P. Tetrahydroxyquinone has anti-leukaemic properties through diminished survival signalling. **Exp Hematol.** 34 (2006): 188-196
 56. Versteeg HH. Emerging insights in the role of Tissue Factor in cancer. **Curr Genom.** 2005;7: 375-382.
 57. Versteeg HH. Inside Blood: Tissue factor and cancer cells. As bad as it gets? **Blood** 2005;105:1374.
 58. Schoenmakers SH, Versteeg HH, Groot A, Reitsma PH, Spek CA. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. **J Thromb Haemost.** 2004;2:2185-2193.
 59. Knapp S, Gibot S, De Vos A, Versteeg HH, Colonna M, Van der Poll T. Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. **J Immunol.** 2004;173:7131-7134.
 60. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue Factor and cancer metastasis; the role of intracellular and extracellular signaling. **Mol Med.** 2004;10:6-11
 61. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Duran N, Peppelenbosch MP. Molecular mechanisms of violacein-mediated human leukemia cell death. **Blood** 2004;104:1459-1464.
 62. Bos CL, Richel DJ, Peppelenbosch MP, Versteeg HH. Prostanoids and Prostanoid Receptors in Signal Transduction. **Int J Biochem Cell Biol.** 2004;36:1187-1205.

Curriculum Vitae Henri Versteeg

63. Versteeg HH, Richel DJ, Peppelenbosch MP, Spek CA. Concerted action of coagulation factors on cell survival. **J Thromb Haemost.** 2004;2:673-674.
64. Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP. FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. **Circ Res.** 2004;94:1032-1040.
65. Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor; implications for inflammation and signal transduction. **Semin Hematol.** 2004;1, Suppl 1:168-172.
66. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation Factors VIIa and Xa inhibit apoptosis and anoikis. **Oncogene** 2004;23:410-417.
67. Diks SH, Hardwick JC, Diab RM, van Santen MM, Versteeg HH, van Deventer SJ, Richel DJ, Peppelenbosch MP. Activation of the canonical beta-catenin pathway by histamine. **J Biol Chem.** 2003;278:52491-52496.
68. Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. **Carcinogenesis** 2003;24:1009-1013.
69. Van den Brande JH, Braat H, Van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, Van Montfrans C, Hommes DW, Peppelenbosch MP, Van Deventer SJ. Infliximab, but not etanercept binds to and induces apoptosis in activated peripheral lymphocytes from healthy volunteers and lamina propria T cells from Chron's disease patients. **Gastroenterol.** 2003;124:1774-1785.
70. Versteeg HH, Bresser HL, Spek CA, Richel DJ, Van Deventer SJ, Peppelenbosch MP. Regulation of the p21Ras-MAP kinase pathway by FVIIa. **J Thromb Haemost.** 2003;1:1012-1018.
71. Peppelenbosch MP, Versteeg HH, Spek CA. In-silico Tissue Factor analysis; a 'bit-by-bit' comparison **Thromb Haemost.** 2003;89:592-593.
72. Van den Blink B, van der Kleij AJ, Versteeg HH, Peppelenbosch MP. Immunomodulatory effect of oxygen and pressure. **Comp Biochem Physiol A Mol Integr Physiol.** 132 (2002): 193-197.
73. Versteeg HH, Sørensen BB, Slofstra SH, Van den Brande JH, Stam JC, van Bergen en Henegouwen PM, Richel DJ, Petersen LC, Peppelenbosch MP. VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. **J Biol Chem.** 2002;277:27065-72702.
74. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? **Thromb Haemost.** 2001;86:1353-1359.
75. Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. **Trends Cardiovasc Med.** 2001;11:335-339.
76. Stam JC, Geerts WJ, Versteeg HH, Verkleij AJ, van Bergen en Henegouwen PM. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt. **J Biol Chem.** 2001;276:25176-25183.
77. Van den Brink GR, O'Toole T, Hardwick JC, van den Boogaardt DE, Versteeg HH, van Deventer SJ, Peppelenbosch MP. Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase. **Mol Cell Biol Res Commun.** 2000;4:144-150.
78. Versteeg HH, Nijhuis E, van den Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, Coffey PJ, Peppelenbosch MP. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. **Biochem J.** 2000;350: 717-722.
79. Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, van Bergen En Henegouwen PM, van Deventer SJ, Peppelenbosch MP. Factor VIIa/tissue factor-

Curriculum Vitae Henri Versteeg

- induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. **J Biol Chem.** 2000;275:28750-28756.
80. Versteeg HH, Evertzen MW, van Deventer SJ, Peppelenbosch MP. The role of phosphatidylinositide-3-kinase in basal mitogen-activated protein kinase activity and cell survival. **FEBS Lett.** 2000;465:69-73.
 81. Versteeg HH, van Bergen en Henegouwen PM, van Deventer SJ, Peppelenbosch MP. Cyclooxygenase-dependent signalling: molecular events and consequences. **FEBS Lett.** 1999;445:1-5.
 82. Whitehead B, Tessari M, Versteeg HH, van Delft S, van Bergen en Henegouwen PM, Vuister GW. Sequence-specific ¹H, ¹³C and ¹⁵N assignment of the EH1 domain of mouse Eps15. **J Biomol NMR** 1998;12:465-466.

Book Chapters

1. Versteeg HH, Spek, CA. The pleiotropic effects of Tissue Factor. Chapter from: 'Molecular Mechanisms of Disseminated Intravascular Coagulation', Landes Biosciences 2001. ISBN: 1-58706-058-2.
-